Abstract
To the Editor:
We congratulate the PRIZE Study Group (Precision Medicine With Zibotentan in Microvascular Angina) on a comprehensive study evaluating the clinical efficacy of zibotentan (a selective endothelin A receptor antagonist) in patients with microvascular angina, although the findings were unfortunately negative. Our group undertook a comparable pilot study but concluded that zibotentan was an effective antianginal medication in a specific microvascular angina endotype, ie, patients with the coronary slow flow phenomenon (CSFP). Comparing the 2 trials provides important insights for future trials.
We congratulate the PRIZE Study Group (Precision Medicine With Zibotentan in Microvascular Angina) on a comprehensive study evaluating the clinical efficacy of zibotentan (a selective endothelin A receptor antagonist) in patients with microvascular angina, although the findings were unfortunately negative. Our group undertook a comparable pilot study but concluded that zibotentan was an effective antianginal medication in a specific microvascular angina endotype, ie, patients with the coronary slow flow phenomenon (CSFP). Comparing the 2 trials provides important insights for future trials.
| Original language | English |
|---|---|
| Pages (from-to) | e28-e29 |
| Number of pages | 2 |
| Journal | Circulation |
| Volume | 152 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 22 Jul 2025 |
| Externally published | Yes |
Keywords
- coronary microvascular dysfunction
- coronary slow-flow phenomenon
- zibotentan